Latest News of AZN
With 72% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing
By Yahoo! Finance |
2 weeks ago
AstraZeneca has 25 investors holding a majority stake of 49%. Institutions own 72% and can influence market moves. Top shareholders include Capital Research and Management, BlackRock, and The Vanguard...
AstraZeneca PLC (AZN): A Top Holding in George Soros's Portfolio
By Yahoo! Finance |
3 weeks ago
George Soros, a renowned investor and philanthropist, holds a net worth of $7.2 billion. AstraZeneca PLC (NASDAQ:AZN) is the top holding in his portfolio, with a 3.43% stake....
Is AstraZeneca PLC (AZN) the Best Cheap Growth Stock to Buy According to Analysts?
By Yahoo! Finance |
1 month ago
AstraZeneca PLC (NASDAQ:AZN) is a cheap growth stock with promising earnings growth projections and a robust pipeline. Analysts recommend buying, expecting a 21% upside. Despite its potential, other A...
-
AstraZeneca PLC (AZN): A Risky Bet on Emerging Cancer Treatments
By Yahoo! Finance | 1 month agoInsider Monkey recently listed the 10 Best Foreign Stocks To Buy Now, including AstraZeneca PLC. The article discusses the current state of global equities, focusing on the impact of the pandemic, int...
-
Is AstraZeneca PLC (AZN) the Best Growth Stock To Buy According To George Soros?
By Yahoo! Finance | 1 month agoGeorge Soros, a renowned investor, has a net worth of $7.2 billion and is known for his investment strategies. AstraZeneca PLC is ranked as the top growth stock pick by Soros, with a significant incre...
-
AstraZeneca (LSE:AZN) Gains FDA Approval for Fasenra in EGPA, Boosting Revenue Growth and Market Position
By Yahoo! Finance | 1 month agoAstraZeneca shows 18% revenue growth, upgraded guidance, and strong pipeline momentum. Challenges include rising costs and debt. Opportunities lie in innovative pipeline expansion and growth in emergi...
-
Could The Market Be Wrong About AstraZeneca PLC (LON:AZN) Given Its Attractive Financial Prospects?
By Yahoo! Finance | 1 month agoAstraZeneca's stock price fell 9.1% recently, but its strong financials suggest potential long-term growth. The Return on Equity (ROE) at 16% is above industry average, indicating good profitability a...
-
AstraZeneca PLC (AZN): Short Seller Sentiment For This Big-Name Stock is Bullish
By Yahoo! Finance | 1 month agoInsider Monkey analyzed short selling data, revealing trends in US-listed stocks and sectors like technology. AstraZeneca PLC is highlighted as a strong stock with growth potential, supported by strat...
-
Is AstraZeneca PLC (AZN) the Best Cancer Stock to Buy Now?
By Yahoo! Finance | 2 months agoAstraZeneca PLC (NASDAQ:AZN) is a leading player in the oncology market, excelling in cancer treatments with innovative drugs like Tagrisso. Their success in developing groundbreaking cancer treatment...
-
Several Reasons for the Outperformance of Astrazeneca Plc (AZN)
By Yahoo! Finance | 2 months agoCarillon Tower Advisers' Q2 2024 investor letter discusses the market performance and highlights AstraZeneca PLC (NASDAQ:AZN) as a promising stock pick. The letter emphasizes the potential of AI stock...
-
AstraZeneca PLC (AZN): A Good 52-Week High Stock to Buy According to Short Sellers
By Yahoo! Finance | 2 months agoAstraZeneca PLC (NASDAQ:AZN) is a top 52-week high stock to buy, driven by strong product portfolio and strategic acquisitions. The company's focus on oncology and other medical fields, along with div...
-
AstraZeneca PLC (LON:AZN) Shares Could Be 49% Below Their Intrinsic Value Estimate
By Yahoo! Finance | 2 months agoA valuation model for AstraZeneca (LON:AZN) using the Discounted Cash Flow method indicates the stock is undervalued by 49% compared to its current price. The analysis considers future cash flows and ...
-
Why Is AstraZeneca PLC (AZN) a Good Addition to Your Stock Portfolio Now?
By Yahoo! Finance | 2 months agoAstraZeneca PLC is a top pharmaceutical company with strong financials and market presence. It is considered an undervalued UK stock with potential growth due to its oncology franchise. Despite uncert...
-
AstraZeneca PLC (AZN): Should You Invest in This GLP-1 and Weight Loss Stock Right Now?
By Yahoo! Finance | 2 months agoAstraZeneca PLC is a top contender in the GLP-1 and weight loss market, aiming for $80 billion in revenue by 2030. The company's innovative obesity medication pipeline places it as a strong player in ...
-
Here's Why AstraZeneca PLC (AZN) Increased in Q2
By Yahoo! Finance | 3 months agoBaron Funds' "Baron Health Care Fund" Q2 2024 investor letter reported a 2.55% decline, underperforming the benchmark due to active sub-industry weights. AstraZeneca PLC was highlighted as a top pick ...